Home › NCT04597372

Impact of Tamsulosin on Post-Operative Urinary Retention Following Pelvic Reconstructive Surgery

The Impact of Tamsulosin on Duration of Post-Operative Urinary Retention in Women Undergoing Pelvic Reconstructive Surgery- A Double Blind, Randomized, Placebo-Controlled Study

Who can join

Ages 18 and older · Women · Healthy volunteers welcome

Inclusion Criteria:

* 18 years or older
* willing and able to provide informed consent
* postoperative urinary retention as defined by a failed RGVT prior to hospital discharge
* Ability to speak and read English
* Tolerate pill ingestion

Exclusion Criteria:

* allergy/intolerance to Tamsulosin or sulfa drugs
* preoperative history of urinary retention as defined by preoperative post void residual of \>150mL
* current use of alpha antagonist medication for hypertension
* severe dementia
* end stage renal or liver disease
* history of severe heart failure or major cardiovascular event in the last 6 months

About the study

The objective of the study is to determine the effectiveness of postoperative Tamsulosin in reducing the duration of acute postoperative urinary retention (POUR) following pelvic reconstructive surgery through a double blind, randomized placebo-controlled trial.

What is being tested

• Tamsulosin (drug)
• Placebo (drug)

Sponsor: Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute) · Participants: 154 · Started: Nov 3, 2021

Contact the study team

• Lindsay Turner · Phone: (412)-330-4567
• AHN Clinical Trials Contact · Phone: (412)-330-4567

Official record on ClinicalTrials.gov — NCT04597372

Locations in the U.S.

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.